Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xenetix 300 vs Visipaque 270 in pediatric multislice CT
2005-000664-51Phase 4Completed
- Sponsor
- Guerbet
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in conditions requiring computed tomography with contrast comparing Xenetix 300 arm with Visipaque 270 arm (2 arms). Primary endpoint: Renal tolerance assessed by creatinine clearance change. Started Nov 2005; status: completed.
02
Drugs
iobitridoliodixanol
03
Conditions
conditions requiring computed tomography with contrast
Beyond the preview
Go deeper on 2005-000664-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000664-51.